终末期肾病患者感染性心内膜炎风险
丹麦全国登记研究纳入1996至2012年10,612例启动肾脏替代治疗(RRT)的终末期肾病患者,心内膜炎总体发生率为627/10万患者年,血液透析者最高(1092/10万患者年),中心静脉导管者风险是动静脉瘘者的两倍以上;RRT前6个月、主动脉瓣病和既往心内膜炎为显著危险因素。
要点
- 血液透析者心内膜炎发生率显著高于腹膜透析和肾移植者。
- 中心静脉导管透析者心内膜炎风险是动静脉瘘者的两倍以上。
- RRT前6个月、主动脉瓣病和既往心内膜炎是显著危险因素。
核心结论
- 接受RRT的患者心内膜炎发生率较高,尤其是使用中心静脉导管的血液透析患者。
- RRT前6个月、主动脉瓣病和既往心内膜炎是发生心内膜炎的显著危险因素。
研究设计与样本
- 基于丹麦全国定期透析与移植登记库的队列研究,纳入1996年1月1日至2012年12月31日启动RRT的10,612例患者(平均年龄63岁,36%女性)。
- RRT方式包括血液透析7233例、腹膜透析3056例、抢先肾移植323例。
- 采用多变量Cox回归模型识别心内膜炎的独立危险因素。
主要发现
- 267例(2.5%)发生心内膜炎,其中31例(12%)接受瓣膜手术。
- RRT患者心内膜炎总体发生率为627/10万患者年。
- 血液透析、腹膜透析和肾移植者的发生率分别为1092/10万患者年、212/10万患者年和85/10万患者年。
- 以腹膜透析为参照,血液透析者心内膜炎调整风险比(HR)为5.46(95%CI 3.28–9.10),肾移植受者为0.41(95%CI 0.18–0.91)。
- 心内膜炎后总体死亡率:院内22%,1年51%。
临床怎么用
- 对血液透析患者,尤其是使用中心静脉导管者,应警惕感染性心内膜炎风险。
- RRT启动后前6个月、合并主动脉瓣病或既往心内膜炎者需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Endocarditis is a serious complication in patients treated with RRT. The study aimed to examine incidence and risk factors of endocarditis in patients with ESRD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Danish National Registry on Regular Dialysis and Transplantation contains data on all Danish patients receiving renal replacement (hemodialysis, peritoneal dialysis, or kidney transplantation) for ESRD. Incidence of endocarditis was estimated for each RRT modality. Independent risk factors of endocarditis were identified in multivariable Cox regression models. RESULTS: From January 1st, 1996 to December 31st, 2012, 10,612 patients (mean age 63 years, 36% female) initiated RRT (7233 hemodialysis, 3056 peritoneal dialysis, 323 pre-emptive kidney transplantation). Endocarditis developed in 267 (2.5%); of these 31 (12%) underwent valve surgery. The overall incidence of endocarditis was 627 per 100,000 person-years in patients receiving RRT. Incidence was higher in patients receiving hemodialysis compared with those receiving peritoneal dialysis or kidney transplantation (1092 per 100,000 person-years, 212 per 100,000 person-years, and 85 per 100,000 person-years, respectively). Adjusted hazard ratios for endocarditis in patients receiving hemodialysis were 5.46 (95% confidence interval [95% CI], 3.28 to 9.10) and 0.41 (95% CI, 0.18 to 0.91) for kidney-transplanted recipients, respectively, as compared with patients in peritoneal dialysis. The incidence of endocarditis in hemodialysis recipients with central venous catheters was more than two-fold higher as compared with those with arteriovenous fistulas. Overall mortality, subsequent to endocarditis, was 22% in-hospital and 51% at 1 year. The first 6 months in RRT, aortic valve disease, and previous endocarditis were identified as significant risk factors of endocarditis. CONCLUSIONS: Patients receiving RRT have a high incidence of endocarditis, in particular during hemodialysis treatment using central venous catheters. The first 6 months in RRT, aortic valve disease, and previous endocarditis are significant risk factors for developing endocarditis.
引用
- Chaudry MS, Carlson N, Gislason GH, et al. Risk of Infective Endocarditis in Patients with End Stage Renal Disease. Clin J Am Soc Nephrol. 2017. PMID: 28974524. doi:10.2215/CJN.02320317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。